Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 and ≤65 years of age at the time of consent.~* Patients with Atopic Dermatitis~* Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit~* Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit~* static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit~Exclusion Criteria:~* Serological evidence of hepatitis B virus or hepatitis C virus infection~* Known human immunodeficiency virus infection~* Ongoing treatment with specific or non-specific hyposensitization therapy for AD~* Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week prior to randomization~* History of infection including skin infection requiring treatment with oral or intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to randomization.~* Evidence of tuberculosis (TB) infection as defined by a positive purified protein derivative (PPD) and/or positive interferon-gamma release assay.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group1 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group2 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group3 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group4 (Type: EXPERIMENTAL): Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
- Group5 (Type: EXPERIMENTAL): Part A: Placebo Part B: nemolizumab (CIM331)

Based on this trial design, predict the completion outcome and termination type (if applicable).